Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

Core Insights - Eagle Pharmaceuticals, Inc. has released its unaudited financial statements for the three months ended March 31, 2025, which are accessible on their investor relations website [1] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical trials, manufacturing, and commercialization [2] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [2] - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (in Japan), and BYFAVO® and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [2] - The company's oncology and CNS/metabolic critical care pipeline features product candidates aimed at addressing underserved therapeutic areas across various disease states [2] - Eagle is focused on developing medicines that could integrate into the personalized medicine paradigm in cancer care [2]